0A8E Stock Chart & Stats
$8.46
-$0.28(-3.33%)
At close: 4:00 PM EDT
$8.46
-$0.28(-3.33%)
Day’s Range― - ―
52-Week Range$5.26 - $10.09
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.80K
Market Cap
$1.56B
Enterprise Value$1.54K
Total Cash (Recent Filing)$121.75M
Total Debt (Recent Filing)$289.44M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume283
30 Day Avg. Volume1,799
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside41.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$387.25M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthStrong Recorlev adoption and broad-based product growth are expanding the commercial base. Raised, tighter guidance indicates management sees durable demand and improved visibility, supporting continued revenue scaling over the next several quarters.
Margins And Cash GenerationHigh product-level margins and positive free cash flow provide resources to fund commercialization and pipeline development. The recovery from prior negative cash flow suggests improving operating discipline, although continued execution is needed to sustain it.
Durable Product ProtectionLong-dated Keveyis intellectual-property protection helps defend a recurring rare-disease revenue stream from competition. Additional XP-8121 patents strengthen pipeline exclusivity and could support future commercial differentiation if clinical development succeeds.
Bears Say
Fragile Balance SheetNegative equity and substantial debt leave a limited capital cushion if operating performance weakens. Although convertible notes were retired, leverage still constrains financial flexibility and could increase dependence on cash generation or future financing.
Inconsistent ProfitabilityThe company has not yet converted improving revenue and gross margins into consistent GAAP profitability. Continued net losses can limit internally funded growth and make results more sensitive to investment levels, financing costs, and non-cash charges.
Higher Growth InvestmentExpanded commercial staffing and XP-8121 development may support long-term growth, but they raise the cost base before returns are proven. Phase III enrollment and timing remain uncertain, creating execution risk and potential pressure on near-term earnings.
Xeris Pharmaceuticals News
0A8E FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest share price was $5.26 and its highest was $10.09 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.56B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.192.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -12.329%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A8E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (41.84% Upside)
$12.00 (41.84% Upside)
Blogger Sentiment
Bullish
GB:0A8E Sentiment 83%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
0A8E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all GB:0A8E earnings summaries0A8E Stock 12 Month Forecast
Average Price Target
$12.00
▲(41.84% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―